How to buy Longeveron stock | $3.98

Longeveron Inc is a biotechnology business based in the US. Longeveron shares (LGVN) are listed on the NASDAQ and all prices are listed in US Dollars. Longeveron employs 12 staff and has a trailing 12-month revenue of around 0.00.

Longeveron stock price (NASDAQ: LGVN)

Use our graph to track the performance of LGVN stocks over time.

Longeveron shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$3.98
52-week range	$3.20 - $10.00
50-day moving average	$3.61
200-day moving average	$5.55
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.55

Buy Longeveron shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Longeveron stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Longeveron price performance over time

Historical closes compared with the close of $3.98 from 2021-10-15

1 week (2021-10-11)	15.36%
1 month (2021-09-17)	9.94%
3 months (2021-07-16)	-36.62%
6 months (2021-04-16)	-38.96%

1 year (2020-10-14)	N/A
2 years (2019-10-14)	N/A
3 years (2018-10-14)	N/A
5 years (2016-10-14)	N/A

Longeveron financials

Revenue TTM	$3.9 million
Gross profit TTM	$1.8 million
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	-266.3%
Book value	$1.29
Market capitalisation	$76.1 million

TTM: trailing 12 months

Shorting Longeveron shares

There are currently 261,014 Longeveron shares held short by investors – that's known as Longeveron's "short interest". This figure is 14.9% up from 227,167 last month.

There are a few different ways that this level of interest in shorting Longeveron shares can be evaluated.

Longeveron's "short interest ratio" (SIR)

Longeveron's "short interest ratio" (SIR) is the quantity of Longeveron shares currently shorted divided by the average quantity of Longeveron shares traded daily (recently around 127948.03921569). Longeveron's SIR currently stands at 2.04. In other words for every 100,000 Longeveron shares traded daily on the market, roughly 2040 shares are currently held short.

To gain some more context, you can compare Longeveron's short interest ratio against those of similar companies.

• Arrowhead Pharmaceuticals (ARWR.US): 6.38
• Moderna (MRNA.US): 1.06
• CureVac N-V (CVAC.US): 9.13

However Longeveron's short interest can also be evaluated against the total number of Longeveron shares, or, against the total number of tradable Longeveron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Longeveron's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Longeveron shares in existence, roughly 10 shares are currently held short) or 0.0945% of the tradable shares (for every 100,000 tradable Longeveron shares, roughly 95 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Longeveron.

Find out more about how you can short Longeveron stock.

Longeveron share dividends

We're not expecting Longeveron to pay a dividend over the next 12 months.

Have Longeveron's shares ever split?

Longeveron's shares were split on a 2:5 basis on 11 March 2008. So if you had owned 5 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Longeveron shares – just the quantity. However, indirectly, the new 150% higher share price could have impacted the market appetite for Longeveron shares which in turn could have impacted Longeveron's share price.

Longeveron overview

Longeveron Inc. , a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida. .

Frequently asked questions

What percentage of Longeveron is owned by institutions?
Currently 10.891% of Longeveron shares are held by institutions. How many people work for Longeveron?
Latest data suggests 12 work at Longeveron. When does the fiscal year end for Longeveron?
Longeveron's fiscal year ends in December. Where is Longeveron based?
Longeveron's address is: 1951 NW 7th Avenue, Miami, FL, United States, 33136 What is Longeveron's ISIN number?
Longeveron's international securities identification number is: US54303L1044 What is Longeveron's CUSIP number?
Longeveron's Committee on Uniform Securities Identification Procedures number is: 54140W107